WHO reinstates important drugs amphotericin B and flucytosine after pressure from leading expert
A Manchester doctor believes the lives of tens of thousands of people worldwide who develop a deadly type of fungal meningitis could now be saved thanks to a U-turn by the World Health Organisation (WHO). Professor David Denning, who is recognised as an international expert in infectious and fungal diseases, has campaigned with others to have two drugs reinstated on the Essential Medicines List following a definitive trial from Vietnam... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 8, 2013 Category: Consumer Health News Tags: Regulatory Affairs / Drug Approvals Source Type: news
Safety of a single very high dose of liposomal amphotericin B for antifungal prophylaxis in patients with acute myeloid leukemia: a prospective phase II single-center study
Annino L, Chierichini A, Anaclerico B, Finolezzi E, Norata M, Cortese S, Cassetta MI, Fallani S, Novelli A, Girmenia C (Source: The Aspergillus Website - articles)
Source: The Aspergillus Website - articles - April 15, 2013 Category: Respiratory Medicine Source Type: news
High-dose induction liposomal amphotericin B followed by de-escalation is effective in experimental Aspergillus terreus pneumonia
Lewis RE, Albert NP, Liao G, Wang W, Prince RA, Kontoyiannis DP (Source: The Aspergillus Website - articles)
Source: The Aspergillus Website - articles - April 15, 2013 Category: Respiratory Medicine Source Type: news
Combo Defeats Fungal Meningitis in HIV (CME/CE)
(MedPage Today) -- Induction therapy with combined amphotericin B and flucytosine improved survival in HIV-positive patients with cryptococcal meningitis, a randomized trial determined. (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - April 3, 2013 Category: Consumer Health News Source Type: news
Treatment of Experimental Aspergillosis
with Amphotericin B
JOHN H. EVANS a n d ROGER D. BAKER (Source: The Aspergillus Website - articles)
Source: The Aspergillus Website - articles - February 27, 2013 Category: Respiratory Medicine Source Type: news
Hepatosplenic fungal infection: CT and pathologic evaluation after treatment with liposomal amphotericin B
Shirkhoda A, Lopez-Berestein G, Holbert JM, Luna MA (Source: The Aspergillus Website - articles)
Source: The Aspergillus Website - articles - February 27, 2013 Category: Respiratory Medicine Source Type: news
The changing epidemiology of fungal infections: are the lipid-forms of amphotericin B an advance?
Herbrecht R (Source: The Aspergillus Website - articles)
Source: The Aspergillus Website - articles - February 25, 2013 Category: Respiratory Medicine Source Type: news
Amphotericin B-induced myelopathy
Carnevale NT, Galgiani JN, Stevens DA, Herrick MK, Langston JW (Source: The Aspergillus Website - articles)
Source: The Aspergillus Website - articles - February 12, 2013 Category: Respiratory Medicine Source Type: news
Amphotericin B nasal spray as prophylaxis against aspergillosis in patients with neutropenia
Meunier-Carpentier F, Snoeck R, Gerain J, Muller C, Klastersky J (Source: The Aspergillus Website - articles)
Source: The Aspergillus Website - articles - February 7, 2013 Category: Respiratory Medicine Source Type: news
Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections
Wiley JM, Seibel NL, Walsh TJ (Source: The Aspergillus Website - articles)
Source: The Aspergillus Website - articles - February 5, 2013 Category: Respiratory Medicine Source Type: news
Direct Healthcare Professional Communication: Interaction between sodium stibogluconate (Pentostam®) and amphotericin B deoxycholate
Source: MHRA
Area: News
GlaxoSmithKline has issued a Direct Healthcare Professional Communication regarding new interaction details for sodium stibogluconate (Pentostam®), which have been added to the product information.
An increased risk of fatal cardiac arrhythmias has been observed when amphotericin B deoxycholate is administered soon after sodium stibogluconate during retreatment of visceral leishmaniasis. Although the mechanism is unknown, it is suggested that sodium stibogluconate increases the susceptibility of the myocardium to damage by amphotericin B deoxycholate.
Sections 4.4 and 4.5 h...
Source: NeLM - News - February 4, 2013 Category: Drugs & Pharmacology Source Type: news
Empiric amphotericin B therapy in patients with acute leukemia
Holleran WM, Wilbur JR, DeGregorio MW (Source: The Aspergillus Website - articles)
Source: The Aspergillus Website - articles - January 10, 2013 Category: Respiratory Medicine Source Type: news
Liposomal amphotericin B (AmBisome) in the treatment of fungal infections in neutropenic patients
Chopra R, Blair S, Strang J, Cervi P, Patterson KG, Goldstone AH (Source: The Aspergillus Website - articles)
Source: The Aspergillus Website - articles - January 10, 2013 Category: Respiratory Medicine Source Type: news
Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients
Perfect JR, Klotman ME, Gilbert CC, Crawford DD, Rosner GL, Wright KA, Peters WP (Source: The Aspergillus Website - articles)
Source: The Aspergillus Website - articles - January 10, 2013 Category: Respiratory Medicine Source Type: news
Intranasal amphotericin B reduces the frequency of invasive aspergillosis in neutropenic patients
Jeffery GM, Beard ME, Ikram RB, Chua J, Allen JR, Heaton DC, Hart DN, Schousboe MI (Source: The Aspergillus Website - articles)
Source: The Aspergillus Website - articles - January 10, 2013 Category: Respiratory Medicine Source Type: news
